

COLUCID PHARMACEUTICALS ANNOUNCES \$16.5 MILLION SERIES A FINANCING

PR Newswire Europe, January 17, 2006

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company focused on new therapeutics for neurological diseases, announced a \$16.5 million Series A financing. The company was formed with a novel clinical stage migraine molecule licensed from Eli Lilly and Company and a portfolio of preclinical assets based on a robust bifunctional neuromodulator chemistry platform, which originated at Sention, Inc. Pappas Ventures seed funded and formed the company. The Series A financing was co-led by Domain Associates and Pappas Ventures with other investors including Triathlon Medical Ventures and Pearl Street Venture Funds.

The Series A funding will be used to further progress the lead molecule through clinical trials and to advance the preclinical chemistry platform to a point of having a clinic-ready program.

CoLucid Pharmaceuticals, Inc.

Arthur Pappas of Pappas Ventures, Jesse Treu of Domain Associates and James White, an independent biopharmaceutical consultant, will be joining the CoLucid Board of Directors.